This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: Q77.3 (chondrodysplasia punctata) | Special Copayment Reduction: V228 (ultra-rare disease) |
| B. Synonyms | Chondrodysplasia punctata, rhizomelic chondrodysplasia punctata (types 1–3, RCDP), X-linked dominant chondrodysplasia (Conradi-Hünermann syndrome, EBP), X-linked recessive chondrodysplasia punctata (ARSE), Chondrodysplasia punctata (CDP), Rhizomelic chondrodysplasia punctata (RCDP), Conradi-Hünermann-Happle syndrome, Binder syndrome (mild) |
| C. Adult onset | Likelihood of first onset in adulthood very low — mostly diagnosed in the neonatal period or infancy. RCDP type 1 (severe) mostly results in death in infancy or childhood. The X-linked dominant (Conradi-Hünermann) and X-linked recessive forms can survive into adulthood but require ongoing management of skin, bone, ophthalmic, and neurological complications. |
| 1. History | First described by Conradi in 1914 → additional report by Hünermann in 1931 → X-linked dominant inheritance established by Happle in 1965 → PEX7 gene linked to RCDP in 1994 → EBP gene (Conradi-Hünermann) identified in 1999 → ARSE gene (X-linked recessive) confirmed in 2000. |
| 2. Causes | A heterogeneous group of diseases. RCDP type 1 (PEX7 variants, peroxisomal targeting receptor-2 deficiency), RCDP types 2/3 (GNPAT, AGPS variants, impaired ether phospholipid synthesis). X-linked dominant: EBP (Xp11.23) variants. X-linked recessive: ARSE (Xp22.33) variants. Common result: stippled calcification of the epiphyses. |
| 3. Genetics | RCDP: autosomal recessive (PEX7 6q22.1, GNPAT 1q42.2, AGPS 2q31.2, etc.). X-linked dominant (EBP, Xp11.23): females survive, lethal in males. X-linked recessive (ARSE, Xp22.33): males affected. Recurrence risk differs for each type. |
| 4. General epidemiology | Overall CDP incidence about 1 in 100,000 births or less. RCDP type 1 is the most common severe form. X-linked dominant (Conradi-Hünermann) mostly in girls. X-linked recessive mostly in boys. No ethnic predilection. Covered by Korean Special Copayment Reduction V228. |
| 5. Pathophysiology | RCDP: defective peroxisomal ether phospholipid (plasmalogen) synthesis → abnormal cell membrane phospholipid composition → impaired cartilage matrix mineralization → stippled epiphyseal calcification. EBP (Conradi-Hünermann): defective 3β-hydroxysteroid-Δ8,7-isomerase → impaired cholesterol and steroid synthesis → accompanied by abnormal fetal vitamin K metabolism. |
| 6. Symptoms | RCDP type 1: rhizomelic shortening (shoulders and hips), severe intellectual disability, seizures, cataracts, skin abnormalities. Conradi-Hünermann (EBP): stippled calcification (neonatal, disappears), ichthyosis, asymmetric limb shortening, scoliosis, cataracts. ARSE (X-linked recessive): mild limb shortening, abnormal nasal septum formation, stippled calcification. |
| 7. Signs | Radiology: stippled calcification of the epiphyses (multiple small dots). RCDP: symmetric proximal limb shortening. Conradi-Hünermann: asymmetric limb shortening, scoliosis. Ophthalmology: cataracts (RCDP, EBP). Skin: linear dyskeratosis (EBP, along Blaschko lines). Neurology: intellectual disability (severe in RCDP type 1). |
| 8. Screening | Prenatal: ultrasound (stippled epiphyseal calcification, limb shortening). Blood plasmalogen analysis (suspected RCDP). With a family history, CVS or amniocentesis + molecular analysis. Prenatal MRI as an adjunct. Not detectable by NIPT. |
| 9. Diagnosis | X-ray (stippled epiphyseal calcification). Serum/erythrocyte plasmalogens (RCDP). Skin/leukocyte VLCFA. Peroxisomal enzyme activity assays. Molecular genetics: PEX7, GNPAT, AGPS, EBP, ARSE variant analysis. WES/panel NGS. |
| 10. Treatment | No curative treatment. RCDP: supplementation with plasmalogen precursors (alkylglycerol) under study. Cataract surgery (infancy). Seizures: anticonvulsants. Brace or surgery for scoliosis. Skin care (emollients). Physical, speech, and occupational rehabilitation. Nutritional support. |
| 11. Prognosis | RCDP type 1 (severe): mostly death in infancy to childhood. Mild RCDP, Conradi-Hünermann, and ARSE forms: survival into adulthood possible. Intellectual function differs by type (severe intellectual disability in RCDP type 1; mostly normal to mild in X-linked dominant and recessive forms). Recurrence risk: RCDP 25%, X-linked dominant maternal 50% (daughters affected), X-linked recessive 50% (sons affected). |
| 12. Prevention | Genetic counseling (explaining recurrence risk by type). RCDP: prenatal diagnosis by PGT-M or CVS/amniocentesis. X-linked dominant: prenatal diagnosis for female carriers of EBP variants. X-linked recessive: prenatal diagnosis for female carriers of ARSE variants. Prevention of abnormal vitamin K metabolism (newborns with the EBP form). Planning of early multidisciplinary intervention. |
| 13. References | Conradi E 1914 Jahrb Kinderheilkd; Braverman N et al. 1997 Nat Genet; Happle R et al. 1983 Hum Genet … and 7 others |
Chondrodysplasia punctata (CDP) was first reported in 1914 when German pediatrician Erich Conradi described skeletal malformations with multiple epiphyseal calcifications in newborns. Then in 1931, Carl Hünermann of Germany reported additional similar cases, establishing the name 'Conradi-Hünermann syndrome'.
However, as subsequent studies accumulated, it became clear that 'CDP' is in fact a collection of several diseases with different etiologies. In 1965, Rudolf Happle proposed that Conradi-Hünermann syndrome is X-linked dominant, based on the clinical observation that the disease presents mainly in girls and is lethal in utero in boys. Happle described the skin abnormalities appearing along Blaschko lines in this disease and explained them as the result of X-chromosome inactivation (lyonization). Accordingly, the disease is now called 'Conradi-Hünermann-Happle syndrome'.
Meanwhile, rhizomelic chondrodysplasia punctata (RCDP) was described in 1971 by Spranger et al. as an independent syndrome characterized by symmetric proximal limb shortening and stippled epiphyseal calcification. An association of RCDP with peroxisomal dysfunction was then proposed in 1984 by Hadler's group, and in 1994 Nancy Braverman's group first identified variants of the PEX7 (peroxisome biogenesis factor 7) gene in RCDP type 1. Subsequently, RCDP type 2 (DHAPAT/GNPAT enzyme deficiency) and RCDP type 3 (AGPS/alkylglyceronephosphate synthase deficiency) were identified in 1997 and 1998, respectively.
The molecular cause of the X-linked dominant form was revealed in 1999 when Nolan's group identified variants of the EBP (emopamil binding protein, Xp11.23) gene in Conradi-Hünermann-Happle syndrome. The X-linked recessive form (including the Binder phenotype) was established as a distinct molecular entity in 2000 with the identification of variants in the ARSE (arylsulfatase E, Xp22.33) gene. This established CDP as a heterogeneous group of diseases divided by etiology into peroxisomal metabolic disorders (RCDP), cholesterol and steroid metabolic disorders (EBP), and sulfatase deficiency (ARSE).
Chondrodysplasia punctata is classified by etiology into three main groups: ① impaired peroxisomal ether phospholipid synthesis (RCDP), ② abnormalities of the cholesterol synthesis pathway (X-linked dominant, EBP), ③ arylsulfatase E deficiency (X-linked recessive, ARSE).
Rhizomelic chondrodysplasia punctata (RCDP) — impaired peroxisomal ether phospholipid synthesis
RCDP type 1 is caused by autosomal recessive variants of the PEX7 (peroxisome biogenesis factor 7, 6q22.1) gene. PEX7 is the receptor that recognizes peroxisomal targeting signal 2 (PTS2) and imports proteins carrying the PTS2 signal (alkyldihydroxyacetone phosphate synthase [AGPS], alkyldihydroxyacetone phosphate synthase precursor, thiolase) into the peroxisome. When PEX7 function is defective, DHAPAT (GNPAT) and AGPS, the key enzymes of ether lipid synthesis, are not properly imported into the peroxisome, and synthesis of ether phospholipids, especially plasmalogens, is completely blocked. Plasmalogens are intrinsic phospholipids of cell membranes and are essential for brain myelination, antioxidant defense, and cell signaling. RCDP type 2 is caused by variants of the GNPAT (1q42.2) gene and RCDP type 3 by variants of the AGPS (2q31.2) gene, which handle the first and second steps of the ether phospholipid synthesis pathway, respectively. RCDP type 4 (PEX5L, RCDP type 5 (PEX5 isoform-related) have also been reported in a small number of cases.
X-linked dominant chondrodysplasia punctata (Conradi-Hünermann-Happle syndrome) — EBP deficiency
The EBP (emopamil binding protein, Xp11.23) gene encodes 3β-hydroxysteroid-Δ8,7-isomerase and catalyzes a late step of the cholesterol synthesis pathway leading from lanosterol to cholesterol. When EBP function is defective, cholesterol synthesis is impaired and sterol intermediates such as 8-dehydrocholesterol (8-DHC) accumulate. This pathology causes abnormal fetal development related to the accumulation of lathosterol and 8-DHC. Because it is X-linked dominant, it presents in heterozygous females, and depending on X-inactivation, the phenotype appears in a mosaic pattern along Blaschko lines. Hemizygous males are lethal in utero.
X-linked recessive chondrodysplasia punctata — ARSE deficiency
The ARSE (arylsulfatase E, Xp22.33) gene encodes arylsulfatase E and is thought to be involved in the steroid sulfation pathway. The exact pathological mechanism of ARSE deficiency has not been fully elucidated, but it has been proposed that this enzyme cooperates with the vitamin K epoxide reductase (VKOR) pathway to activate vitamin K-dependent proteins needed for fetal cartilage matrix mineralization. In ARSE deficiency, cartilage matrix mineralization is transiently impaired, resulting in stippled epiphyseal calcification. This form is the mildest, and patients often survive into adulthood.
Chondrodysplasia punctata is a heterogeneous group of diseases that includes several types with different modes of inheritance. An accurate understanding of the mode of inheritance and molecular genetics of each type is essential for family counseling and predicting recurrence risk.
RCDP type 1 (PEX7, 6q22.1) — autosomal recessive: when both parents are carriers, there is a 25% recurrence risk in children. The most common PEX7 variant is the L292ter (L292X) nonsense variant, a founder variant found in about 50% of patients of Northern European origin. Compound heterozygous variants are also common, and homozygous loss-of-function variants produce a severe phenotype. RCDP type 2 (GNPAT) and RCDP type 3 (AGPS) are also each autosomal recessive, with a recurrence risk of 25%.
X-linked dominant form (EBP, Xp11.23): EBP variants are inherited in an X-linked dominant manner and present in heterozygous females. 50% of the daughters of an affected woman may be affected, and 50% of the sons are hemizygous and die in utero. Many cases arise from de novo variants, in which case the recurrence risk is low. Because of skewed X-chromosome inactivation (lyonization), phenotype severity varies between individuals, which is well reflected in the mosaic skin findings along Blaschko lines. Transmission from father to daughter is also possible.
X-linked recessive form (ARSE, Xp22.33): X-linked recessive, affecting males. Carrier females are mostly asymptomatic but may show mild findings. All daughters of an affected male are carriers, and sons are not affected. In carrier females, 50% of sons are affected. Some cases arise from de novo variants.
Molecular diagnostic strategy: when CDP is clinically suspected, biochemical tests for etiological classification (plasma plasmalogens, phytanic acid, VLCFA — abnormal in RCDP type 1; plasma sterol profile — abnormalities such as 8-DHC in the EBP form) are performed first. Then, depending on clinical and biochemical findings, targeted analysis of the relevant gene or NGS with a gene panel for CDP/peroxisomal disorders is performed. If molecular confirmation is not achieved, testing is extended to WES.
Chondrodysplasia punctata is an ultra-rare group of diseases occurring overall in about 1 in 100,000 births or less. The incidence of each type is estimated as follows.
Incidence by type: RCDP type 1 is the most common severe type at about 1 in 100,000 births, and RCDP types 2 and 3 are each rarer. The X-linked dominant form (Conradi-Hünermann) is estimated at about 1 in 400,000 births and is mostly diagnosed in girls. The X-linked recessive form (ARSE) occurs in boys and is a rare type among all CDP. All CDP types combined are estimated at around 1 in 100,000 births.
Sex and ethnicity: RCDP occurs with equal frequency in males and females and is not limited to any particular ethnic group. The X-linked dominant form is diagnosed almost entirely in girls (lethal in utero in boys), with no ethnic bias. The X-linked recessive form presents in boys. RCDP incidence may be higher in populations with frequent consanguineous marriage. The L292X founder variant is common in RCDP type 1 patients of Northern European origin.
Situation in Korea: in Korea, CDP is eligible for registration support under Special Copayment Reduction V228 (ultra-rare disease). The number of registered patients in Korea is extremely small, and most are diagnosed in the neonatal period or infancy based on characteristic clinical and radiological findings. Because stippled epiphyseal calcification in the neonatal period can occur not only in CDP but also in Zellweger syndrome, vitamin K deficiency, maternal anticoagulant exposure, SLO syndrome (Smith-Lemli-Opitz), and others, differential diagnosis is important.
Distinction from acquired stippled calcification: stippled epiphyseal calcification is not a finding unique to CDP and can also appear transiently with maternal vitamin K antagonist (warfarin) administration, fetal alcohol syndrome, Zellweger syndrome, children of mothers with insulin-dependent diabetes, Down syndrome, and others. Distinguishing these acquired causes from hereditary CDP is possible through biochemical testing and molecular genetics.
The pathophysiology of chondrodysplasia punctata differs by type, but the common end result is abnormal mineralization of the cartilaginous epiphyses and deposition of stippled calcification.
RCDP — mechanism of peroxisomal ether phospholipid (plasmalogen) deficiency: plasmalogens (alkenyl acyl phospholipids) are ether phospholipids that make up about 20% of mammalian cell membrane phospholipids and are highly expressed in the brain (mainly ethanolamine plasmalogens), heart, skeletal muscle, sperm, and elsewhere. Plasmalogen synthesis begins in the peroxisome: GNPAT (DHAPAT) produces alkyl-DHAP from acyl-DHAP, and AGPS catalyzes the reaction synthesizing alkyl-DHAP. When PEX7 function is deficient in RCDP type 1, these two enzymes cannot be imported into the peroxisome, and plasmalogen synthesis is completely blocked. Plasmalogen deficiency reduces cell membrane fluidity, increases vulnerability to reactive oxygen species (ROS), disturbs membrane cholesterol distribution, and impairs Wnt signaling, damaging the differentiation of growth plate chondrocytes and the mineralization of the extracellular matrix. Chondrocyte mitochondrial function is also impaired by plasmalogen deficiency, disturbing cellular energy metabolism. Other peroxisomal functions such as VLCFA (very-long-chain fatty acid) oxidation, phytanic acid oxidation, and bile acid synthesis may also be partially impaired.
Conradi-Hünermann (EBP) — mechanism of impaired cholesterol synthesis: the EBP enzyme (Δ8,7-isomerase) catalyzes an intermediate step of the lanosterol-to-cholesterol pathway in the late stage of cholesterol synthesis. In EBP deficiency, sterol intermediates such as 8-dehydrocholesterol (8-DHC) and 8-dehydrodesmosterol accumulate. These intermediates disrupt Hedgehog (Hh) signaling during fetal development and also affect retinoid signaling and the activity of vitamin K-dependent proteins (osteocalcin, matrix Gla protein), making cartilage matrix mineralization abnormal. Because it is X-linked dominant, expression is uneven in a mosaic pattern due to X-inactivation, which causes the skin findings along Blaschko lines and the asymmetric limb shortening.
ARSE — mechanism of arylsulfatase E deficiency: ARSE is thought to be involved in the metabolism of sulfated proteoglycans in the cartilage matrix and has been proposed to affect activation of vitamin K-dependent proteins (matrix Gla protein, MGP) by regulating the function of vitamin K epoxide reductase (VKOR). Because MGP suppresses abnormal calcification of the cartilage matrix, reduced MGP function in ARSE deficiency causes abnormal stippled calcification of the cartilaginous epiphyses.
The symptoms of chondrodysplasia punctata differ greatly in severity and pattern of involvement by type.
Symptoms of RCDP type 1 (severe): the most characteristic finding is rhizomelia (proximal limb shortening), in which the upper arms and thighs are disproportionately short compared with the forearms and lower legs. This gives a markedly shortened appearance at the shoulders and hips. Severe intellectual disability and seizures occur in most patients with RCDP type 1, explained by impaired brain development due to plasmalogen deficiency (incomplete myelination, abnormal pons formation, etc.). Cataracts are found in almost all patients with RCDP type 1, reflecting impaired lens epithelial cell function due to lens plasmalogen deficiency. Ichthyosis or dry, scaly skin is present. Joint contractures, especially flexion contractures of the elbows and knees, are common. Growth retardation is marked, and average height is markedly short.
Symptoms of the X-linked dominant form (Conradi-Hünermann-Happle): it presents in girls, and ichthyosiform skin changes along Blaschko lines appear from the neonatal period. These skin findings partially disappear with growth or change to patchy atrophic skin. Limb shortening is asymmetric, often with one limb shorter than the other. Scoliosis progresses gradually. Cataracts occur in about 30–50%. Facial hypoplasia, a flat nasal septum, and frontal bossing are characteristic. Hair is dry and brittle, and alopecia occurs in some cases. Intelligence is mostly normal or mildly delayed.
Symptoms of the X-linked recessive form (ARSE): it presents mainly in boys, and the clinical symptoms are much milder than in the other forms. Abnormal nasal septum formation and a flat nose (platyrrhinia) are characteristic. There may be mild limb shortening. Stippled epiphyseal calcification appears in the neonatal period but disappears with growth. Intelligence is normal. Patients with this form survive into adulthood and can engage in relatively normal social activities.
The objective signs of chondrodysplasia punctata are confirmed by radiology, physical examination, ophthalmologic examination, skin examination, and biochemical testing.
Radiological signs — stippled epiphyses: this is the key radiological finding from which chondrodysplasia punctata takes its name. On X-ray, multiple small, irregular calcified dots (stippling) are seen in the epiphyses (endochondral ossification centers), paravertebral cartilage, tracheal cartilage, periarticular cartilage around the ankles, and elsewhere. This finding is most evident in the neonatal period to infancy and tends to disappear gradually with growth. In RCDP, calcification is seen symmetrically, mainly around the proximal joints (shoulders, hips). The EBP form shows an asymmetric, uneven distribution. Stippled calcification of the spine appears mainly around the vertebral bodies.
Musculoskeletal signs: in RCDP, proximal shortening of the upper arms and thighs is marked, and on X-ray the humerus and femur are short and thick with wide, irregular metaphyses. In the EBP form, asymmetric limb shortening and scoliosis appear as signs. Joint contractures (especially elbows and knees) are common in RCDP.
Ophthalmic signs: cataracts appear bilaterally as posterior cortical cataracts or nuclear cataracts and are confirmed by slit-lamp examination. Nystagmus, strabismus, and optic nerve hypoplasia are present in some cases.
Skin signs: in the EBP form, hyperkeratotic or scaly skin (ichthyosiform plaques) in linear and whorled arrangements along Blaschko lines is characteristic. In RCDP, generalized dry skin and ichthyosis are present. Hair abnormalities (dry, brittle, twisted hair) are also seen in the EBP form.
Neurological signs: in RCDP type 1, severe developmental delay, hypotonia, and seizures appear early. Brain MRI may show delayed/incomplete myelination and abnormal cerebellar development. In the EBP and ARSE forms, neurological findings are mostly absent or mild.
Biochemical findings: in RCDP, erythrocyte plasmalogen levels are markedly reduced, plasma phytanic acid is increased, and plasma VLCFA is normal (normal in RCDP type 1). In the EBP form, elevated plasma 8-DHC and 8-dehydrodesmosterol are found. In the ARSE form there are no specific biochemical findings, but abnormal plasma sulfated DHEA levels have been reported.
There is no general population screening program for chondrodysplasia punctata; prenatal ultrasound and biochemical and molecular screening based on family history are the main methods.
Prenatal ultrasound: detailed ultrasound at 16–22 weeks of gestation may detect stippled calcification around the epiphyses (ultrasonographic stippling), but because of the resolution limits of ultrasound, sensitivity for detecting stippled calcification is limited. Limb shortening (especially proximal shortening in RCDP) may be observed. When stippled calcification is found, CDP must be differentiated from acquired causes such as maternal vitamin K antagonist use and fetal alcohol exposure.
Biochemical screening: when RCDP is suspected, measurement of plasmalogen synthesis activity in prenatal amniocytes or infant serum, or measurement of plasma plasmalogen concentrations, is useful. Measurement of plasma phytanic acid concentration is also used as an adjunct for diagnosing RCDP type 1. When the EBP form is suspected, plasma sterol profile analysis (confirming elevated 8-DHC and 8-dehydrodesmosterol) is performed.
Molecular screening based on family history: when the causative gene variant has been identified in a previously affected child, prenatal confirmation in the next pregnancy is possible by targeted gene analysis after chorionic villus sampling (CVS, 11–14 weeks) or amniocentesis (15–20 weeks). For RCDP, preimplantation genetic testing (PGT-M) can also be applied. In the X-linked dominant form (EBP), an affected mother has a 50% chance of affected daughters, so prenatal diagnosis is recommended during pregnancy. In the X-linked recessive form (ARSE), 50% of the sons of a carrier mother are affected, so prenatal diagnosis is possible.
Confirmation of chondrodysplasia punctata is made by integrating clinical and radiological findings, biochemical testing, and molecular genetic analysis.
Clinical and radiological diagnosis: when the triad of proximal limb shortening, stippled epiphyseal calcification (X-ray), and cataracts is present in the neonatal period or infancy, RCDP is strongly suspected. The EBP form is suspected in girls with asymmetric limb shortening and Blaschko-line skin findings, and the ARSE form in boys with a flat nose and mild limb shortening. A full skeletal survey confirms the distribution of stippled calcification and the type of limb shortening.
Biochemical diagnosis: ① erythrocyte plasmalogen analysis (C16:0 DMA, C18:0 DMA fractions) — markedly reduced in RCDP types 1–3. ② Plasma phytanic acid measurement — may be moderately elevated in RCDP type 1. ③ Plasma sterol analysis — confirms elevated 8-DHC and 8-dehydrodesmosterol in the EBP form. ④ Measurement of peroxisomal enzyme (DHAPAT, AGPS) activity in fibroblasts or leukocytes — confirms the RCDP type.
Molecular genetic diagnosis: based on biochemical test results, targeted analysis of the gene corresponding to the suspected type (PEX7 — RCDP type 1; GNPAT — RCDP type 2; AGPS — RCDP type 3; EBP — X-linked dominant form; ARSE — X-linked recessive form) is performed, or NGS with a gene panel for CDP/peroxisomal disorders. If biochemical and targeted analyses are negative, testing is extended to WES to search for additional variants. After molecular diagnosis is confirmed, recurrence risk is calculated by parental variant analysis and genetic counseling is provided.
Differential diagnosis: ① Fetus exposed to vitamin K antagonists (warfarin): acquired stippled calcification, normal plasmalogens and sterols. ② Zellweger syndrome: severe peroxisomal dysfunction, systemic VLCFA elevation. ③ SLO (Smith-Lemli-Opitz) syndrome: elevated 7-dehydrocholesterol, DHCR7 variants. ④ Down syndrome: transient stippled calcification, trisomy 21. Each condition is differentiated by biochemical and molecular findings.
There is currently no curative treatment for chondrodysplasia punctata. Treatment differs according to the clinical phenotype of each type and consists mainly of symptomatic treatment and prevention and management of complications.
RCDP — plasmalogen supplementation research: because plasmalogen deficiency is the core biochemical abnormality of RCDP, a therapeutic approach of restoring plasmalogens through oral supplementation of alkylglycerol precursors is being studied. Some effects have been observed in animal models, but clinical efficacy in humans has not yet been established. Several clinical studies have been underway since the 2020s.
Cataract treatment: cataracts are treated early with lens extraction and correction with glasses or contact lenses. Surgery within the first few months of life is recommended for visual development, followed by regular ophthalmologic follow-up. Associated ophthalmic problems such as nystagmus and strabismus are also managed.
Seizure treatment: seizures, common in RCDP type 1, are controlled with anticonvulsants such as valproic acid, levetiracetam, and clonazepam. The drug is chosen according to seizure type (focal seizures, generalized seizures, infantile spasms, etc.). Multidisciplinary collaboration with an epilepsy specialist is needed.
Scoliosis management: progressive scoliosis is common in the EBP form. For mild to moderate scoliosis, bracing and physical therapy are used, and spinal fusion is considered when the curve progresses beyond 40 degrees or affects pulmonary function.
Skin care: when ichthyosis is present, skin moisturizing and scale removal are carried out continuously with emollient creams and keratolytics (salicylic acid, urea-containing creams). The Blaschko-line skin lesions of the EBP form partially disappear with growth, but specialist dermatologic care is helpful.
Rehabilitation and supportive care: in RCDP, early intervention with physical, occupational, and speech therapy for severe developmental delay is important for maintaining daily functioning. Nutritional support (tube feeding or gastrostomy feeding) is needed in some cases. In the EBP and ARSE forms, relatively normal schooling is possible, though special education support is needed in some cases.
The prognosis of chondrodysplasia punctata varies greatly with type and severity.
Prognosis of RCDP type 1 (severe): this is the type with the poorest prognosis. Most patients with RCDP type 1 die in infancy or childhood (mostly before age 5), with the main causes of death being recurrent aspiration pneumonia, respiratory failure, and status epilepticus. Long-term survival is rare, and even surviving patients remain fully dependent owing to severe intellectual disability, seizures, and motor impairment. A small number of cases surviving into adolescence have been reported in rare mild RCDP type 1 variants (with residual enzyme activity).
Prognosis of the X-linked dominant form (Conradi-Hünermann): this type allows survival into adulthood. The neonatal Blaschko-line skin findings and stippled calcification disappear or improve with growth. Scoliosis may progress, in which case orthopedic management affects long-term function. Intelligence is mostly normal to mildly delayed, and many patients can engage in normal social and occupational activities. Periodic ophthalmologic follow-up (cataracts), dermatologic follow-up, and spinal radiographic evaluation are central to long-term management.
Prognosis of the X-linked recessive form (ARSE): this is the mildest phenotype, and most patients survive into adulthood. Stippled epiphyseal calcification resolves spontaneously after infancy, and limb shortening does not cause major functional limitation. Intelligence is normal. The flat nose (midface dysplasia) persists, but functional problems are minor. Overall quality of life is relatively good.
Recurrence risk: RCDP (autosomal recessive): 25% recurrence risk in the next pregnancy. X-linked dominant (EBP): 50% risk for daughters of an affected mother. X-linked recessive (ARSE): 50% risk for sons of a carrier mother. Family counseling and prenatal diagnosis are therefore important in all types.
Prevention of chondrodysplasia punctata is achieved through genetic counseling and prenatal diagnosis/preimplantation genetic testing. Prevention strategies differ according to the recurrence risk of each type.
Genetic counseling: when chondrodysplasia punctata is confirmed, comprehensive counseling with a medical geneticist and genetic counselor is essential. The mode of inheritance (RCDP: autosomal recessive 25%; X-linked dominant: 50% of daughters of affected women; X-linked recessive: 50% of sons of carrier mothers) and the recurrence risk are explained accurately. Carrier testing of the extended family (siblings, maternal grandparents, etc.) is also recommended.
Preimplantation genetic testing (PGT-M): in RCDP, when the variants of both parents have been identified, affected embryos can be excluded at the preimplantation stage by PGT-M. In the X-linked recessive form (ARSE), with a carrier mother and an unaffected father, it is also possible to determine by PGT whether male embryos are affected and then implant unaffected male or female embryos. In the X-linked dominant form (EBP) as well, unaffected embryos can theoretically be selected for an affected mother.
Prenatal diagnosis: when a previously affected child has been confirmed molecularly, whether the fetus is affected is confirmed prenatally in the next pregnancy by targeted gene analysis after CVS (11–14 weeks) or amniocentesis (15–20 weeks). When RCDP is suspected, analysis of plasmalogen synthesis enzyme activity in amniocytes or chorionic villus cells may be used as an adjunct.
Vitamin K metabolism considerations (EBP form): in Conradi-Hünermann-Happle syndrome, reduced activity of vitamin K-dependent proteins due to EBP deficiency may be associated with epiphyseal calcification, so administering vitamin K at the standard dose in the neonatal period is recommended. This does not reverse the calcification itself but prevents hemorrhagic complications due to deficiency of vitamin K-dependent coagulation factors.
Early multidisciplinary intervention plan: after confirmation or prenatal diagnosis, a multidisciplinary team of pediatrics, ophthalmology, neurology, orthopedics, dermatology, rehabilitation medicine, and genetics is formed from the neonatal period and infancy to establish an integrated management plan from the outset. This contributes to early detection and treatment of complications, family support, and improved long-term prognosis.
Braverman N, Steel G, Obie C, et al. Human PEX7 encodes the peroxisomal PTS2 receptor and is responsible for rhizomelic chondrodysplasia punctata. Nat Genet. 1997;15(4):369-376. DOI: 10.1038/ng0497-369. PMID: 9090381.
Nolen G, Ward S, Dempsey W, et al. Novel missense mutation in EBP causes X-linked dominant chondrodysplasia punctata (Conradi-Hünermann-Happle syndrome). Am J Med Genet. 2002;110(1):73-79. DOI: 10.1002/ajmg.10159. PMID: 12116276.
Happle R. X-linked dominant chondrodysplasia punctata. Review of literature and report of a case. Hum Genet. 1979;53(1):65-73. DOI: 10.1007/BF00393688. PMID: 535541.
Waterham HR, Ferdinandusse S, Wanders RJA. Human disorders of peroxisome metabolism and biogenesis. Biochim Biophys Acta. 2016;1863(5):922-933. DOI: 10.1016/j.bbamcr.2015.11.015. PMID: 26611709.
Braverman NE, Moser AB, Steinberg SJ. Rhizomelic chondrodysplasia punctata type 1. In: Adam MP et al., eds. GeneReviews. Seattle: University of Washington; 2001 [updated 2019]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1270/. PMID: 20301382.
Has C, Hartl F, Bröcker EB, et al. Conradi-Hünermann-Happle syndrome: novel mutations, novel morphological findings. Clin Exp Dermatol. 2008;33(4):434-439. DOI: 10.1111/j.1365-2230.2008.02827.x. PMID: 18466379.
Mortier GR, Cohn DH, Cormier-Daire V, et al. Nosology and classification of genetic skeletal disorders: 2019 revision. Am J Med Genet A. 2019;179(12):2393-2419. DOI: 10.1002/ajmg.a.61366. PMID: 31633310.
Unger S, Ferreira CR, Mortier GR, et al. Nosology of genetic skeletal disorders: 2023 revision. Am J Med Genet A. 2023;191(5):1164-1209. DOI: 10.1002/ajmg.a.63132. PMID: 36779427.
Wanders RJA, Brites P. Biosynthesis of ether-phospholipids including plasmalogens and the role of the autophagy receptor NBR1 in their regulation. Front Cell Dev Biol. 2010;8:547070. DOI: 10.3389/fcell.2020.547070. PMID: 33195235.
Balci S, Oguz KK, Figen Tuysuz B, Sakallioglu O. Rhizomelic chondrodysplasia punctata: clinical, biochemical and radiological study and report of 17 Turkish patients. Am J Med Genet A. 2007;143A(13):1476-1485. DOI: 10.1002/ajmg.a.31802. PMID: 17568436.